Open AccessMyeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Author(s) -
Maen Hussein,
Marina Maglakelidze,
Donald A. Richards,
Marielle Sabatini,
Todd A Gersten,
Keith A. Lerro,
Ivan Sinielnikov,
Alexander I. Spira,
Yili Pritchett,
Joyce Antal,
Rajesh Malik,
J. Thaddeus Beck
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s313045
Subject(s) - medicine , placebo , chemotherapy , anemia , neutropenia , incidence (geometry) , lung cancer , gastroenterology , clinical endpoint , febrile neutropenia , randomized controlled trial , surgery , pathology , physics , alternative medicine , optics
Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression (CIM) by protecting hematopoietic stem and progenitor cells and immune system function from chemotherapy-induced damage (myeloprotection). Here, we investigated the myeloprotective effects of trilaciclib among patients at increased risk of CIM.